Acquired von Willebrand Disease Treatment
Treatment of Underlying Condition
- The American Society of Hematology recommends that therapy directed at the underlying clone is the most effective approach for acquired von Willebrand disease (AvWD) associated with monoclonal gammopathy or lymphoproliferative disorders, with rituximab monotherapy recommended for IgM-related disease 1
- For non-IgM gammopathies, antimyeloma agents such as bortezomib are recommended as first-line therapy when there is renal involvement, while lenalidomide-based regimens are preferred when there is neuropathy 1
- In young patients (≤65-70 years) with severe, progressive, or debilitating symptoms, high-dose melphalan with autologous stem cell transplantation may be considered 1
Management of Acute Bleeding
- The International Society on Thrombosis and Haemostasis recommends that for acute bleeding episodes, the therapeutic algorithm depends on the underlying etiology, with intravenous immunoglobulin (IGIV) being the most effective therapy for patients with underlying lymphoproliferative disorder or monoclonal gammopathy 1
- The European Hematology Association recommends that desmopressina (DDAVP) is used as second-line treatment for bleeding in AvWD when IGIV is not available or has failed, with a dose of 0.3 μg/kg IV diluted in 50 mL of saline solution, infused over 30 minutes 2
Prophylaxis Before Procedures
- The American College of Cardiology recommends that before surgery or invasive procedures in patients with AvWD, strategies should be established to prevent bleeding episodes using FvW/FVIII concentrates as prophylaxis, with FvW activity ≥50 UI/dL required for neuroaxial anesthesia 2
Critical Safety Considerations
- The National Hemophilia Foundation recommends that aspirin should be used with extreme caution or avoided in patients with AvWD who have an increased risk of bleeding, and that platelet count should be monitored in patients with extreme thrombocytosis (platelets >1 million/μL) before initiating any medication that affects hemostasis 4
- The International Society on Thrombosis and Haemostasis recommends that laboratory confirmation of AvWD type should never be assumed without recent laboratory confirmation, as the bleeding phenotype can change over time 4